ATP7A Antibody

What is ATP7A and why are specific antibodies essential for its study?

ATP7A (Copper-transporting ATPase 1) functions as a transmembrane copper-translocating P-type ATPase that plays a vital role in systemic copper absorption in the gut and copper reabsorption in the kidney . ATP7A is primarily located in the trans-Golgi network and basolateral membrane of polarized epithelial cells . While ATP7A is not detectable in most normal tissues, it is expressed in many common tumor types, where increased expression can render cells resistant to cisplatin and carboplatin .

Specific antibodies are essential because ATP7A has multiple isoforms (including isoforms 1, 2, 3, and 5) with molecular weights ranging from 54.3 kDa to 172 kDa . This diversity requires carefully validated antibodies to ensure specificity in different experimental contexts.

Which experimental applications are most common for ATP7A antibodies?

ATP7A antibodies have been validated for multiple research applications, with varying effectiveness:

Research shows that ATP7A antibodies can effectively detect the protein in multiple species with high homology, including human, mouse, rat, cow, dog, horse, pig, and sheep samples .

What controls should be included when validating a new ATP7A antibody?

When validating ATP7A antibodies, multiple controls are critical for ensuring experimental reliability:

• Positive tissue/cell controls: SH-SY5Y neuroblastoma cells show reliable ATP7A expression and cytoplasmic staining pattern .

• Negative tissue/cell controls: HepG2 liver cells show low or undetectable ATP7A expression .

• Genetic controls: ATP7A knockout or siRNA-treated cells (e.g., HeLa cells transfected with siRNA targeting ATP7A) provide the gold standard for antibody specificity validation .

• Peptide competition assays: Using the ATP7A antigenic peptide can confirm antibody specificity by blocking antibody binding .

• Loading controls: GAPDH, Calnexin, or alpha-Tubulin antibodies should be used alongside ATP7A detection .

Recent studies demonstrate that properly validated antibodies show no signal in ATP7A knockout A549 cell lines at the expected molecular weight of 163 kDa .

How should researchers optimize Western blot protocols for ATP7A detection?

ATP7A detection in Western blots requires specific optimization strategies:

• Sample preparation: Avoid boiling samples as this may cause protein aggregation . Use non-reducing conditions when possible.

• Protein loading: Load at least 20 µg of total protein per lane for reliable detection .

• Detection sensitivity: Use high-sensitivity ECL substrates that allow for detection in the mid-femtogram range for optimal visualization .

• Antibody concentration: Most validated antibodies work optimally at 1:1000 dilution for Western blot application .

• Expected band size: ATP7A typically appears between 140-170 kDa, with the canonical band at approximately 163 kDa. Additional bands may appear between 37-100 kDa, though their identity remains unknown .

• Best practices: For challenging samples, consider membrane stripping and re-probing with alternative ATP7A antibody clones to confirm specificity.

What are the key methodological considerations for immunofluorescence studies of ATP7A?

For optimal immunofluorescence detection of ATP7A:

• Fixation protocol: Use 4% paraformaldehyde fixation followed by 0.1% TritonX-100 permeabilization .

• Antibody concentration: Typically 1:500 dilution (approximately 10 μg/ml) yields optimal staining with minimal background .

• Co-staining recommendations: ATP7A can be co-stained with alpha-tubulin (using Alexa Fluor® 594-conjugated antibodies) to visualize its relationship to the cytoskeleton .

• Expected staining pattern: Look for cytoplasmic staining pattern in positive cell lines like SH-SY5Y, with particular emphasis on trans-Golgi network localization under basal conditions .

• Copper-induced trafficking: Following copper treatment, ATP7A antibodies can detect the protein's redistribution from the trans-Golgi network to the plasma membrane, making ATP7A antibodies valuable tools for studying copper-responsive trafficking .

How can researchers use ATP7A antibodies to study its interactome?

The ATP7A interactome can be studied using antibody-based approaches:

• Cross-linking immunoaffinity chromatography: Use DSP or formaldehyde to cross-link protein complexes before immunoprecipitation with ATP7A antibodies .

• Technical considerations: Monospecific monoclonal antibodies are preferred as they provide robust recognition that can be abolished in ATP7A-null cells .

• Validation approaches:

  • Surface biotinylation followed by streptavidin precipitation and immunoblot against ATP7A can confirm antibody effectiveness in detecting copper-induced surface expression .

  • Control experiments should include incubations with excess antigenic peptide to identify non-specific interactors .

• Data analysis: Quantitative mass spectrometry after ATP7A immunoprecipitation has identified 541 positive interacting proteins, with minimal overlap (5.7%) with common contaminants in the CRAPome database .

• Important findings: Recent research using this approach has identified that the ATP7A interactome encompasses a novel COG-dependent mechanism that specifies neuronal development and survival .

How do ATP7A antibodies facilitate research on Menkes disease mechanisms?

ATP7A antibodies are instrumental in studying Menkes disease, a fatal childhood disorder caused by mutations in the ATP7A gene:

• Mutation detection: Different antibodies targeting various domains can help identify how specific mutations affect protein expression, stability, and localization.

• Functional studies: ATP7A antibodies can assess copper-induced trafficking defects in patient-derived cells, where mutations often impair the protein's ability to relocalize in response to copper .

• Therapeutic research: In experimental treatments for Menkes disease, antibodies can monitor whether therapeutic interventions restore normal ATP7A expression or function.

• Tissue expression profiling: The relatively low expression of ATP7A in most normal tissues but critical roles in specific cell types (like intestinal enterocytes and renal tubular cells) makes antibody-based detection crucial for understanding disease pathophysiology .

• Related disorders: ATP7A antibodies also help distinguish between Menkes disease and other copper disorders like Wilson disease (caused by ATP7B mutations), allowing researchers to study how these proteins interact in copper homeostasis .

How can ATP7A antibodies be used to investigate cancer chemotherapy resistance?

Increased ATP7A expression confers resistance to platinum-based drugs like cisplatin and carboplatin:

• Expression correlation studies: ATP7A antibodies can quantify protein levels across tumor samples and correlate them with treatment response data.

• Mechanism investigation: Immunofluorescence and co-localization studies with ATP7A antibodies can determine whether the protein sequesters chemotherapy agents in intracellular compartments.

• Knockdown validation: Comparing ATP7A antibody signals between control and ATP7A-silenced cancer cells can confirm successful experimental manipulation before drug sensitivity testing.

• Therapeutic development: High-throughput screening for compounds that alter ATP7A localization or expression can be monitored using antibody-based assays.

• Clinical significance: Recent studies identifying ATP7A expression in tumors where it is normally absent suggest that antibody-based detection may have prognostic value .

What are the most common technical challenges when working with ATP7A antibodies?

Researchers commonly encounter these challenges when working with ATP7A antibodies:

• Multiple bands in Western blot:

  • The high molecular weight of ATP7A (163 kDa) makes complete transfer difficult

  • Unknown bands between 37-100 kDa may appear

  • Solution: Use gradient gels and extend transfer time; validate with knockout/knockdown controls

• Variability between antibody clones:

  • Different epitopes may yield different results

  • Some antibodies detect multiple isoforms while others are isoform-specific

  • Solution: Validate each new antibody against known positive and negative controls

• Tissue-specific expression:

  • Low expression in most normal tissues makes detection challenging

  • Solution: Use high-sensitivity detection methods and appropriate positive control tissues

• Sample preparation impact:

  • Boiling can cause protein aggregation

  • Solution: Use non-boiled samples for Western blot

• Background in immunostaining:

  • Non-specific binding can occur

  • Solution: Increase blocking time/concentration and carefully titrate primary antibody

How can researchers design experiments to investigate ATP7A trafficking in response to copper?

To study copper-induced trafficking of ATP7A:

• Experimental design:

  • Treat cells with copper (typically CuCl₂, 100-200 μM) for various time points (0, 30, 60, 120 minutes)

  • Include copper chelator (BCS) as negative control

  • Process cells for either immunofluorescence or cell surface biotinylation

• Surface biotinylation protocol:

  • Treat live cells with membrane-impermeable NHS-SS-biotin

  • Lyse cells and precipitate biotinylated proteins with streptavidin

  • Detect ATP7A in precipitates via Western blot

  • Include transferrin receptor as copper-insensitive control

• Subcellular fractionation alternative:

  • Separate membrane fractions after copper treatment

  • Detect ATP7A redistribution between fractions

  • Use TGN markers (e.g., TGN46) and plasma membrane markers as controls

• Advanced imaging options:

  • Live-cell imaging using fluorescently-tagged ATP7A

  • Super-resolution microscopy to visualize trafficking vesicles

  • FRAP (Fluorescence Recovery After Photobleaching) to measure mobility

• Data interpretation: Successful experiments should show increased ATP7A at the cell surface or plasma membrane fraction after copper treatment, while transferrin receptor distribution remains unchanged .

How might ATP7A antibodies contribute to understanding the ATP7A-dependent interactome in neuronal development?

Recent research has identified that the ATP7A interactome encompasses a novel COG-dependent mechanism specifying neuronal development and survival :

• Experimental approach: Immunoaffinity chromatography with crosslinked ATP7A complexes from neuroblastoma cells (SH-SY5Y), followed by mass spectrometry .

• Key findings: 541 proteins were identified in the ATP7A interactome, with minimal overlap with common contaminants .

• Validation approaches:

  • Co-immunoprecipitation with reverse pull-down

  • Proximity ligation assays to confirm interactions in situ

  • CRISPR-mediated tagging of ATP7A for BioID or APEX2 proximity labeling

• Neuronal development applications:

  • Using ATP7A antibodies to track developmental expression patterns

  • Correlating ATP7A-interacting proteins with neurodevelopmental stages

  • Investigating ATP7A trafficking in response to neuronal activity

• Future directions: Exploring how this interactome changes in different neuronal subtypes or under various pathological conditions could provide insights into neurodegeneration and neurodevelopmental disorders.

What emerging methodologies combine ATP7A antibodies with other techniques for comprehensive copper homeostasis studies?

Emerging methodologies integrating ATP7A antibodies with complementary techniques include:

• Spatial proteomics:

  • Combining ATP7A immunofluorescence with metal imaging techniques (e.g., LA-ICP-MS)

  • Correlating ATP7A localization with local copper concentrations

  • Implementation: Requires specialized equipment but provides unprecedented insights into copper distribution relative to ATP7A

• Multi-omics integration:

  • Correlating ATP7A antibody-based proteomics with transcriptomics and metabolomics

  • Identifying how ATP7A expression/localization affects global cellular processes

  • Implementation: Requires computational integration of multiple data types

• Organoid and 3D culture systems:

  • Using ATP7A antibodies to track copper transport in physiologically relevant models

  • Visualizing ATP7A in polarized epithelial layers that better recapitulate in vivo conditions

  • Implementation: Requires adaptation of immunostaining protocols for 3D structures

• Single-cell analysis:

  • Combining flow cytometry with ATP7A antibodies to assess cell-to-cell variability

  • Correlating ATP7A levels with single-cell transcriptomics

  • Implementation: Requires optimization of antibody staining for flow applications

• In vivo imaging:

  • Developing ATP7A antibody-based tracers for non-invasive imaging

  • Monitoring copper fluxes in living organisms

  • Implementation: Still experimental but holds promise for translational research